 EMERYVILLE, Calif., Sept. 22, 2021 PRNewswire -- Dynavax Technologies Corporation Nasdaq: DVAX, a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Clover Biopharmaceuticals Clover reported positive data for their protein-based COVID-19 vaccine candidate, SCB-2019 CpG 1018Alum adjuvanted with Dynavaxs CpG 1018 adjuvant, which achieved the primary and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 23 clinical trial that enrolled over 30,000 participants. 